CriticalOther antidepressants (NaSSA)×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Mirtazapine blocks central presynaptic alpha-2 adrenergic receptors and so increases noradrenergic and serotonergic transmission. The serotonergic effect runs through 5-HT1 receptors, because mirtazapine blocks 5-HT2 and 5-HT3 receptors (mirtazapine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) A and B and stops the enzyme from breaking down serotonin, noradrenaline and dopamine (tranylcypromine SmPC, AEMPS). MAO inhibitors impair serotonin metabolism and, together with serotonergic antidepressants including mirtazapine, increase the risk of serotonin syndrome (mirtazapine label, US Food and Drug Administration, FDA). The elimination half-life of mirtazapine is 20–40 hours, occasionally up to 65 hours (mirtazapine SmPC, AEMPS). Full MAO activity returns 3–5 days after the last dose of tranylcypromine (tranylcypromine SmPC, AEMPS). According to the US label, MAO inhibition may persist for up to 10 days (tranylcypromine FDA label).
Symptoms
Serotonin syndrome can be life-threatening (mirtazapine label, US Food and Drug Administration, FDA). According to the Spanish mirtazapine summary of product characteristics (SmPC), it presents with high body temperature, rigidity, myoclonus, nervous system instability with possible rapid fluctuations of vital signs, and mental changes ranging from confusion, irritability and extreme agitation to delirium and coma (mirtazapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US label adds hallucinations, fast heart rate, labile blood pressure, dizziness, sweating, flushing, tremor, overactive reflexes, poor coordination, seizures, nausea, vomiting and diarrhoea (mirtazapine FDA label). Fatal serotonin syndrome has been reported, including in people treated with tranylcypromine (tranylcypromine FDA label).
Management
The combination is contraindicated. The Spanish mirtazapine summary of product characteristics (SmPC) lists combined use with monoamine oxidase inhibitors (MAOIs) among its contraindications (mirtazapine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and tranylcypromine is an irreversible, non-selective MAOI according to its own SmPC (tranylcypromine SmPC, AEMPS). The US mirtazapine labels contraindicate mirtazapine in patients taking MAOIs or within 14 days of stopping them and name tranylcypromine among the examples. The US tranylcypromine label lists mirtazapine in its table of contraindicated drugs (mirtazapine and tranylcypromine labels, US Food and Drug Administration, FDA). The Spanish tranylcypromine SmPC does not mention mirtazapine (tranylcypromine SmPC, AEMPS). Start mirtazapine no earlier than 2 weeks after stopping tranylcypromine (mirtazapine SmPC, AEMPS; mirtazapine FDA label). After stopping mirtazapine, start tranylcypromine after about 2 weeks (mirtazapine SmPC, AEMPS), or no earlier than 14 days according to the US mirtazapine label (mirtazapine FDA label). The Spanish tranylcypromine SmPC recommends a drug-free interval of about 5 half-lives of the previous antidepressant and its active metabolites (tranylcypromine SmPC, AEMPS). If serotonin syndrome develops, stop mirtazapine and other serotonergic drugs and start supportive symptomatic treatment (mirtazapine SmPC, AEMPS; mirtazapine and tranylcypromine FDA labels). Treat severe serotonin syndrome caused by an interaction with serotonergic drugs as tranylcypromine poisoning: in intensive care, with close monitoring of pulse, blood pressure, breathing and temperature, and with mechanical ventilation available (tranylcypromine SmPC, AEMPS, overdose section).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Remeron/RemeronSolTab (mirtazapine) prescribing information (2025)– FDA, DailyMed, Remeron/RemeronSolTab, Organon LLC, setid 98ad1917-a094-44f5-a28f-a64a8cfcd887, revisión 08/2025, secciones 4, 5.3, 5.8, 7 y 12.3
- AEMPS: Ficha técnica de Rexer Flas 15 mg comprimidos bucodispersables (mirtazapina) (2021)– AEMPS, CIMA, nº registro 64819, revisión 04/2021, secciones 4.3, 4.5 y 5.1
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1